Medibio Announces Scientific Advisory Board
- Led by Board of Director Franklyn Prendergast, M.D., Ph.D. and Chief Medical Officer Archie Defillo, M.D.
- Key external members include Martin Chapman, M.D.; Joel Ehrenkranz, M.D.; Mark A. Frye, M.D.; Lawrence Hunter, Ph.D.; Wallace Mendelson, M.D.; Marie Casey Olseth, M.D., and Giampaolo Perna, M.D., Ph.D.
SYDNEY, Australia and MINNEAPOLIS, April 25, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX:MEB) (OTCQB:MDBIF), a mental health technology company confirms establishment of its Scientific Advisory Board (SAB).
Scientific Advisory Board Charter/Purpose
The Medibio Scientific Advisory Board is charged to advise the board of directors and executive leadership team on scientific matters involving the Company's discovery and development of programs, including major internal projects, interactions with academic and other outside research organizations, and the acquisition of technologies. The SAB will assist directors and management to stay abreast of industry and mental health research developments, new technologies, and anticipate emerging concepts and trends in mental health, to help assure that Medibio leadership makes well informed choices in committing its resources.
The SAB will also advise the board on scientific matters involving the safety and effectiveness of the Company's marketed products and will assist leadership to exercise reasonable oversight of product safety and medical risk management.
Jack Cosentino, CEO and Managing Director stated, "Our Scientific Advisory Board brings expertise in specialties ranging from computational informatics and neuroscience, to clinicians practicing in primary care and behavioral health. We are honored to have an advisory team with this high level of talent and experience guiding our scientific programs and advising our long-term strategic goals."
Scientific Advisory Board Members
Martin Chapman, MBBS FRANZCP is a psychiatrist and Fellow of the Royal Australian and New Zealand College of Psychiatrists. As a medical administrator he has worked in both hospital and community settings in private and government sectors. His clinical practice is in the area of treatment resistant mood and anxiety disorders. He has taught in undergraduate and postgraduate Psychiatry with a focus in assisting primary care physicians in their management of mental health conditions. He has an interest in mental health system development and the role of new technologies in streamlining and providing clinical decision support.
Joel R. Ehrenkranz, M.D. is an endocrinologist on the faculty of the U. of Colorado School of Medicine and biotech entrepreneur in Salt Lake City, Utah. He received his M.D. from Stanford and trained in internal medicine at Columbia University, neurology at Memorial Sloan Kettering Cancer Center, and endocrinology at the N.I.H.
Mark A. Frye, M.D. is chair of the Department of Psychiatry and Psychology at Mayo Clinic. He also serves as director of the Mayo Clinic Depression Center. Dr. Frye received his M.D. from the University of Minnesota and completed his psychiatric training at the Semel Institute for Neuroscience and Human Behavior at the David Geffen School of Medicine at UCLA. He subsequently completed a fellowship at the National Institute of Mental Health in Bethesda, Maryland with a research focus on the neurobiology of treatment resistant depression and bipolar disorder.
Lawrence Hunter, Ph.D. is a Professor at the University of Colorado and directs the Computational Bioscience Program. He earned his degrees from Yale University, including B.A. in Psychology (cum laude); M.S. and M. Phil. and Ph.D. in Computer Science.
Wallace Mendelson, M.D. is a psychiatrist and author, and was formerly Professor of Psychiatry and Clinical Pharmacology, and director of the Sleep Research Laboratory, at the University of Chicago. Dr. Mendelson earned an MD degree from Washington University School of Medicine in St. Louis and completed a residency in psychiatry there as well. He has held professorships at Ohio State University and the State University of New York at Stony Brook, was Chief of the Section on Sleep Studies at the National Institute of Mental Health in Bethesda, MD, and Director of the Sleep Disorders Center at the Cleveland Clinic.
Marie Casey Olseth, M.D. is currently in private practice as a Board Certified Adult Psychiatrist in the group practice that she owns. She earned her Doctor of Medicine degree from the University of Minnesota Medical School and completed her residency in General Psychiatry at the University of Minnesota and University of Wisconsin, Madison.
Giampaolo Perna, M.D., Ph.D. is currently Chair of the Department of Clinical Neurosciences at San Benedetto Menni Hospital of the Hermanas Hospitalarias (Como Lake) and Academic Coordinator of Mental Health Area and Adjunct Professor at Humanitas University (Milan), in Italy. He earned his degree in Medicine and Surgery at the State University of Milan, followed by a Ph.D. and completed a residency in Psychiatry there as well. He is the Chair of WPA section on personalized psychiatry and Co-editor in chief of the Elsevier Journal "Personalized Medicine in Psychiatry".
Archie Defillo, M.D. is currently the Chief Medical Officer at Medibio Limited. He has over 25 years of clinical experience with neurological diseases. For the past 13 years his efforts have been focused in neurological research. His research interests include cerebrovascular, stroke, neuro-trauma, brain oxygenation, metabolism and autonomic dysfunction.
Peta Slocombe, M.S. is a fully registered Psychologist, member of the Australian Psychological Society and a registered National Health Practitioner with over 20 years' experience. She is currently Senior Vice President, Corporate Health with Medibio Limited.
Franklyn Prendergast, M.D., Ph.D. is currently a director on the Medibio Limited board and chair of the Scientific Advisory Board. Previously, he was the Emeritus Edmond and Marion Guggenheim Professor of Biochemistry and Molecular Biology and Emeritus Professor of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical School, to its Physician Advisory Board.
Dr. Prendergast earned his medical degree with honors from the University of West Indies. He attended Oxford University as a Rhodes Scholar, where he earned his masters degree in Physiology. After completing residency in Internal medicine at The Mayo Clinic in Rochester, Minnesota he earned a doctorate degree Biochemistry from the University of Minnesota/Mayo Graduate School.
Positions held: Chair, Department of Biochemistry and Molecular Biology; Director for Research Mayo Clinic (Rochester) (1989-1992). Board of Governors Mayo Clinic in Rochester; Mayo Clinic Board of Trustees (1992-2009); Mayo Clinic Board of Governors (1999-2006). Mayo Distinguished Investigator; Emeritus Director, Mayo Clinic Comprehensive Cancer Center and Mayo Center for Individualized Medicine.
In addition to his current role as a director on the Medibio board and chair of the Scientific Advisory Board, Dr. Prendergast holds numerous appointments with Industry and Extramural academic affiliations. He has extensive interactions over many years with National Institutes of Health (NIH): Board of Advisors for the Division of Research Grants; National Advisory General Medical Sciences Council; Board of Scientific Advisors of the National Cancer Institute; and the National Cancer Advisory Board.
Medibio (ASX:MEB) (OTCQB:MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company offers comprehensive mental health solutions for business through its Corporate Health programs and is developing products to serve both the consumer and regulated healthcare provider markets. The company was founded in Australia, with offices located in Melbourne (Vic), Perth (WA), and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.
Further Information: Website: www.medibio.com.au Medibio Shareholder Enquiries: Stephanie Ottens Investor Relations Director Medibio Limited firstname.lastname@example.org T: +61 434 405 400 Australian Media Enquiries: Peter Taylor NWR Communications email@example.com T: +61 (0) 412 036 231
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medibio Limited via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
PubMatic Launches OpenBid, Bringing Full Strength of Programmatic Monetization to the Mobile App Environment21.2.2019 15:00:00 | Pressemelding
The Programmatic-First SDK Offers App Developers Benefits of Header Bidding REDWOOD CITY, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- PubMatic, the publisher-focused sell-side platform (SSP) for an open digital media future, today announced the launch of OpenBid, a breakthrough programmatic-first solution that provides app publishers and developers with a gateway to programmatic demand and brand ad budgets. Consumers globally are increasingly interacting with media via mobile devices, and many brand advertisers are turning to in-app advertising to reach this highly-engaged audience. Many are focusing their budgets on automated buying channels such as the open exchange and private marketplaces, with over 90 percent of global media buyers planning to increase their programmatic direct in-app budgets in 2019 (Forrester Consulting). However, many app developers have been unable to fully capitalize on the growing interest from brand advertisers as they rely on legacy mobile mediation partners
Intrinsyc Announces Immediate Availability of Premium-Tier System on Module based on Qualcomm Technologies’ SDA83521.2.2019 13:30:00 | Pressemelding
Designed for use in XR Applications, IP Cameras, Enterprise Tablets, Medical Imaging, and other Next-Generation IoT Devices VANCOUVER, British Columbia, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Intrinsyc Technologies Corporation (TSX: ITC and OTCQX: ISYRF) (“Intrinsyc” or the “Company”), a leading provider of solutions for the development and production of embedded and Internet of Things (IoT) products, today announced the availability of the Open-Q™ 835 µSOM (micro System on Module) and Development Kit. Intrinsyc’s Open-Q™ 835 µSOM is an ultra-compact (50mm x 25mm) production-ready embedded computing module that is ideal for powering premium performance IoT devices. It is powered by the Qualcomm® SDA835 system on chip (SoC) from Qualcomm Technologies, Inc. “Intrinsyc’s Open-Q™ 835 µSOM is Intrinsyc’s most advanced embedded computing module; enabling the highest combination of computing performance, thermal efficiency and power optimization,” said Cliff Morton, Vice President, Solutions Engin
IMImobile releases unified RCS Messaging API to accelerate RCS adoption for enterprise customer communications21.2.2019 11:09:00 | Pressemelding
Unified RCS Messaging API and low-code toolset available in IMImobile’s enterprise cloud communications platform IMIconnect will enable businesses to launch RCS customer journeys up to 10 times faster LONDON, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Global cloud communications software and solutions provider IMImobile PLC, today releases a unified RCS Messaging API alongside its low-code toolset, in its enterprise cloud communications platform, IMIconnect, to drive the adoption of RCS business messaging by leading enterprises globally. Rich Communication Service (RCS) has been widely anticipated as the evolution for SMS messaging to deliver rich customer experiences to today’s digitally savvy consumers. According to Mobilesquared, there will be 1.01bn people using RCS messaging across 168 mobile operators globally by the end of 2019. This is expected to grow to 3.23bn across 486 mobile operators by the end of 2023.1 With the release of its unified RCS API in the IMIconnect platform, enterpris
Tenaris Announces 2018 Fourth Quarter and Annual Results20.2.2019 22:29:00 | Pressemelding
The financial and operational information contained in this press release is based on audited consolidated financial statements presented in U.S. dollars and prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standard Board and adopted by the European Union, or IFRS. Additionally, this press release includes non-IFRS alternative performance measures i.e., EBITDA, Net cash / debt and Free Cash Flow. See exhibit I for more details on these alternative performance measures. LUXEMBOURG, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Tenaris S.A. (NYSE, Buenos Aires and Mexico: TS and MTA Italy: TEN) (“Tenaris”) today announced its results for the fourth quarter and year ended December 31, 2018 with comparison to its results for the fourth quarter and year ended December 31, 2017. Summary of 2018 Fourth Quarter Results (Comparison with third quarter of 2018 and fourth quarter of 2017) 4Q 2018 3Q 2018 4Q 2017 Net sales ($ million) 2,105 1,899
New Samsung Galaxy Ultrasonic Fingerprint System World’s First to Achieve FIDO Biometric Certification20.2.2019 21:30:00 | Pressemelding
Samsung’s new “in-display” Ultrasonic Fingerprint system certified by FIDO Alliance as meeting globally recognized standards for biometric recognition performance and Presentation Attack Detection (PAD) MOUNTAIN VIEW, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- The FIDO Alliance announced today that the Samsung Galaxy S10 and S10+ smartphones are the first products to feature certification from the FIDO Alliance’s new Biometric Component Certification Program. This certification validates that the new in-display fingerprint recognition system meets industry standards for user verification and detecting presentation (or “spoof”) attacks. “As mobile devices increasingly become our primary means of storing sensitive information and conducting critical transactions, the industry leaders in FIDO Alliance have determined the market needs a standard-based means to assess the efficacy of biometric certification components -- which is why we recently launched our Biometric Component Certification
Infovista Expands 5G Network Testing and Planning Capabilities20.2.2019 15:00:00 | Pressemelding
ASHBURN, Va., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Infovista, the leader in modern network performance, today announced new versions of its TEMS Investigation and Planet solutions. With this announcement, Infovista is the only vendor offering the complete 5G portfolio comprising full network planning and testing in a single, integrated platform. Infovista is now uniquely positioned to help mobile network operators roll out 5G NR networks by including the ability to provide integrated Geodata, 5G Planning and Network Testing capabilities. Tweet This: @Infovista expands 5G network testing and planning capabilities, offering complete 5G portfolio in a single, integrated platform: https://bit.ly/2Nm8Rup With the new release of TEMS Investigation, Infovista introduces support for 5G smartphones based on the Qualcomm X50 chipset. With initial support of Qualcomm based devices and plans for agnostic device support, customers will be able to choose between different test devices and scanners to s